DUBLIN, Ireland - (Business Wire) Research and Markets (
http://www.researchandmarkets.com/research/b7b104/all_change_in_the) has announced the addition of the "All Change in the US Pharma Market?" report to their offering.
This extensive report provides a unique analysis of the likely impact of generic competition in the US pharma market.
Now you can:
- Identify the 150 products which could be subject to generic competition over the next 5 years
- Evaluate the level of impact on each product
- Assess the impact of generic competition on 14 leading branded companies
- Understand the strategies being used by companies in defence of their products’ position
Key questions answered in this report:
- Which companies are at greater or lesser risk of generic competition by 2012 and what will be the impact on revenues?
- What strategies has Abbott successfully employed in defence of Depakote and Tricor?
- Who is benefiting from the unresolved biosimilar approval process?
- AstraZeneca could have US$5.31 billion of revenue at risk by 2012 – what are the products affected and when will the impact be felt?
- What lessons can be learned from the ongoing Apotex/BMS and SA litigation in relation to the world’s second best selling drug Plavix?
- There is much discussion about generic competition to Lipitor, but what other products are at risk in Pfizer’s portfolio?
- Why has Wyeth not sued Sun Pharmaceutical over its extended release tablet for Effexor?
A unique business analysis of this crucial issue:
At this critical stage, everyone - be they a branded manufacturer, generics company or commercial investor - needs to understand in detail which products are affected and the mounting effect it will have on the leading pharmaceutical companies. This new 188-page report, written by leading generic market analyst Andy Crofts, compares and contrasts at the product level the current situation and looks at how the market will develop to 2012. Packed with facts, figures and novel analysis, this report is essential reading for all senior executives throughout the industry.
A generic version of a product does not necessarily mean widespread generic availability. For example, we estimate that 43 of the 150 products analysed in this report will face limited competition by 2012. ‘Limited’ indicates that generics will appear by 2012, but will have a muted impact. This could be due to expiry occurring right at the end of the period, a small number of entrants due to 180-day exclusivity or otherwise, generic availability of an older version than the marketed brand, or limited appeal for generics on therapeutic grounds. Is attack the best form of defence?
In the face of ANDA applications made well in advance of significant patent expiry the industry has pursued a wide range of defence strategies including incremental development, reformulation, citizens petitions and deals.
The obvious defence is to sue for patent infringement, but US courts have proved variable in their support of the branded industry IP claims and lengthy and costly litigation has many downsides. At the other end of the scale, companies have sought collaboration as the way forward.
For more information visit http://www.researchandmarkets.com/research/b7b104/all_change_in_the
Source: Espicom Business Intelligence Ltd
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
Fax (USA): 646-607-1907
Fax (International): +353-1-481-1716
